How should the use of the DecisionDx-Melanoma test be integrated into clinical practice to potentially avoid sentinel lymph node biopsy?  

At this time, DecisionDx should be used as an extra piece of molecular information, not for clinical decision-making. The study done on DecisionDx was mainly retrospective, not prospective, so it has limited value in guiding patient care at this time. I would base your decision on SLBx on the curren...

This remains an area of research. Unfortunately, very few diagnostic tests are studied properly. These new genomic tests are usually more expensive. It is important to show that these tests modify the long-term outcome while avoiding a lead-time bias. This is very important in order not to overtreat...

We don't recommend using DecisionDx-Melanoma testing for deciding on sentinel node biopsy due to the lack of properly designed prospective studies. The Breslow depth is the best indicator for conducting SLNB.